Daniel Vasella
Director/Board Member at PEPSICO, INC.
Net worth: 14 M $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Marlene Krauss | M | 79 |
KBL Healthcare Ventures
KBL Healthcare Ventures Investment ManagersFinance KBL Healthcare Ventures (KBL Healthcare) is a venture capital firm founded in 1991 by Zachary C. Berk and Marlene R. Krauss. The firm is headquartered in New York. | 33 years |
Ramon Laguarta | M | 60 | 28 years | |
Stephen Squeri | M | 64 | 39 years | |
Gregory Rockson | M | - |
mPharma Health Nigeria Ltd.
mPharma Health Nigeria Ltd. Packaged SoftwareTechnology Services mPharma Health Nigeria Ltd. engages in the development of a pharmaceutical data management platform. The company was founded by Gregory Rockson, Dan Shoukimas and James Finucane in 2013 and is headquartered in Accra, Ghana.
mPharma Data, Inc.
mPharma Data, Inc. Packaged SoftwareTechnology Services mPharma Data, Inc. engages in the development of an application that enables physicians to prescribe and locate medicines for patients. The company is headquartered in Lexington, MA. | - |
Hans Jörg Reinhardt | M | 68 | 40 years | |
David Urech | M | - |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | 13 years |
Rong Rong Pan | F | 46 | - | |
Oliver Middendorp | M | - |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | 13 years |
James Caulfield | M | 64 | 14 years | |
Chad Cowan | M | - |
Clade Therapeutics, Inc.
Clade Therapeutics, Inc. BiotechnologyHealth Technology Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation. | - |
David Flavell | M | 52 | 13 years | |
Reto Naef | M | - |
TOPADUR Pharma AG
TOPADUR Pharma AG Pharmaceuticals: MajorHealth Technology TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then. | 9 years |
Jim Glasheen | M | - |
Clade Therapeutics, Inc.
Clade Therapeutics, Inc. BiotechnologyHealth Technology Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation. | - |
Fabrizio Bonanni | M | 78 |
XBiotech USA, Inc.
XBiotech USA, Inc. BiotechnologyHealth Technology Part of XBiotech, Inc., XBiotech USA, Inc. is a company that manufactures antibodies. The company is based in Austin, TX. The company was founded in 2005. The CEO is John Simard. | 11 years |
Hong Zhao | M | 60 | 4 years | |
Peter Lichtlen | M | 56 |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | 13 years |
Rosie Perez | F | 43 | - | |
Peter Chu | M | - |
Eclipse Bioinnovations, Inc.
Eclipse Bioinnovations, Inc. Packaged SoftwareTechnology Services Eclipse Bioinnovations, Inc. is a private biotechnology company that develops first-in-class technologies to accelerate the development of RNA genomics discoveries and medicines. The company is based in San Diego, CA. The company offers its end-to-end RNA genomics products as services and kits and also provides custom RNA genomics services for select partners. Laboratory at UC San Diego. Eclipse Bio is an RNA next-generation sequencing (NGS) company founded in 2017 based on technologies and algorithms developed in Dr. The company was founded by Alexander Shishkin, Peter Chu, and Eugene W. Yeo. Peter Chu has been the CEO since incorporation. | - |
Jennifer Bailey | F | 61 | 1 years | |
Paul Guy Desmarais | M | 69 |
INSEAD
| - |
Vasant Narasimhan | M | 48 | 19 years | |
Alberto Weisser | M | 67 | 13 years | |
Dan Shoukimas | M | - |
mPharma Health Nigeria Ltd.
mPharma Health Nigeria Ltd. Packaged SoftwareTechnology Services mPharma Health Nigeria Ltd. engages in the development of a pharmaceutical data management platform. The company was founded by Gregory Rockson, Dan Shoukimas and James Finucane in 2013 and is headquartered in Accra, Ghana. | 11 years |
David Fabricant | M | 53 | 6 years | |
Osiris Marroquin Belaunzaran | M | - |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | - |
Christoph Renner | M | - |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | - |
Wendy Hayes | F | 54 | 3 years | |
Yushao Gu | M | 55 | - | |
Rene Lammers | M | - | 14 years | |
Eugene Yeo | M | 47 |
Eclipse Bioinnovations, Inc.
Eclipse Bioinnovations, Inc. Packaged SoftwareTechnology Services Eclipse Bioinnovations, Inc. is a private biotechnology company that develops first-in-class technologies to accelerate the development of RNA genomics discoveries and medicines. The company is based in San Diego, CA. The company offers its end-to-end RNA genomics products as services and kits and also provides custom RNA genomics services for select partners. Laboratory at UC San Diego. Eclipse Bio is an RNA next-generation sequencing (NGS) company founded in 2017 based on technologies and algorithms developed in Dr. The company was founded by Alexander Shishkin, Peter Chu, and Eugene W. Yeo. Peter Chu has been the CEO since incorporation. | - |
Susan Diamond | F | 50 | 1 years | |
Robert Pohlad | M | 69 | 9 years | |
Monique Herena | F | 53 | 5 years | |
Dina Dublon | F | 70 | 19 years | |
Ping Chen | M | 66 | - | |
Pietro Antonio Tataranni | M | - | 6 years | |
Christophe Le Caillec | M | 58 | 8 years | |
Laureen Seeger | F | 62 | 10 years | |
Walter Clayton | M | 57 | 2 years | |
Sean R. Smith | M | - |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | - |
Charles Phillips | M | 64 | 4 years | |
Christian Ludin | M | - |
TOPADUR Pharma AG
TOPADUR Pharma AG Pharmaceuticals: MajorHealth Technology TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then. | 5 years |
Alexander Shishkin | M | - |
Eclipse Bioinnovations, Inc.
Eclipse Bioinnovations, Inc. Packaged SoftwareTechnology Services Eclipse Bioinnovations, Inc. is a private biotechnology company that develops first-in-class technologies to accelerate the development of RNA genomics discoveries and medicines. The company is based in San Diego, CA. The company offers its end-to-end RNA genomics products as services and kits and also provides custom RNA genomics services for select partners. Laboratory at UC San Diego. Eclipse Bio is an RNA next-generation sequencing (NGS) company founded in 2017 based on technologies and algorithms developed in Dr. The company was founded by Alexander Shishkin, Peter Chu, and Eugene W. Yeo. Peter Chu has been the CEO since incorporation. | - |
Bill Winters | M | 62 | 11 years | |
Ian Cook | M | 71 | 16 years | |
John Simard | M | 62 |
XBiotech USA, Inc.
XBiotech USA, Inc. BiotechnologyHealth Technology Part of XBiotech, Inc., XBiotech USA, Inc. is a company that manufactures antibodies. The company is based in Austin, TX. The company was founded in 2005. The CEO is John Simard. | - |
Reinhard Ambros | M | 67 |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | 5 years |
Darren Walker | M | 64 | 8 years | |
Theodore Leonsis | M | 68 | 14 years | |
Deborah Majoras | F | 59 | 2 years | |
Cesar Conde | M | 50 | 8 years | |
David Lewis | M | 59 | 4 years | |
David Page | M | 67 | 10 years | |
Michelle Gass | F | 56 | 5 years | |
J. Agbaje | M | 59 | 4 years | |
Charles Sawyers | M | 65 | 11 years | |
Douglas Buckminster | M | 63 | - | |
Karen Parkhill | F | 58 | 4 years | |
Edith Cooper | F | 62 | 3 years | |
Angela Hu | F | 40 | 9 years | |
Shirin Bohra | F | - | 12 years | |
Christopher Young | M | 52 | 6 years | |
Thomas Baltimore | M | 60 | 3 years | |
Lynn Carter | F | 67 | 4 years | |
Guo En Liu | M | 67 | - | |
Leandro Vetcher | M | - |
Clade Therapeutics, Inc.
Clade Therapeutics, Inc. BiotechnologyHealth Technology Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation. | - |
John Brennan | M | 69 | 7 years | |
Lisa Wardell | F | 54 | 3 years | |
Samir Shah | M | 63 | 20 years | |
Harry Werner Kirsch | M | 59 | 21 years | |
Barbara Kux | F | 70 |
INSEAD
| 10 years |
Deepak Shantilal Parekh | M | 78 |
INSEAD
| - |
Stanislav Shekshnia | M | 60 |
INSEAD
| - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Steven Reinemund | M | 75 | 31 years | |
Kenneth Chenault | M | 72 | 37 years | |
Indra Krishnamurthy Nooyi | F | 68 | 25 years | |
Alexandre F. Jetzer-Chung | M | 83 |
Novartis Pharmaceuticals UK Ltd.
Novartis Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom. | 16 years |
Richard Petrino | M | 56 | 24 years | |
Richard Goodman | M | 75 | 19 years | |
Hugh Johnston | M | 62 | 36 years | |
Giancarlo Mocchi | M | 84 | 3 years | |
Enderson Guimaraes | M | 64 | 3 years | |
Derek West | M | 58 | 3 years | |
Ronen Tamir | M | 57 | - | |
David Yawman | M | 55 | 23 years | |
Rolf M. Zinkernagel | M | 80 | 15 years | |
Linda Zukauckas | F | 63 | 9 years | |
Wendelin Wiedeking | M | 72 | 11 years | |
Ulrich Lehner | M | 78 | 13 years | |
Joseph Jimenez | M | 64 | 11 years | |
Michael White | M | 72 | 19 years | |
Susan Sobbott | F | 59 | 28 years | |
Peter Maag | M | 57 |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | 11 years |
Verena A. Briner | M | 72 | 3 years | |
Jürgen Brokatzky-Geiger | M | 72 | 14 years | |
Dimitri Azar | M | 65 | 7 years | |
Enrico Cipro Vanni | M | 73 | - | |
Juan Andres | M | 59 | 12 years | |
Thomas Wellauer | M | 69 | - | |
Gary Sutton | M | - | 13 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 59 | 59.00% |
Switzerland | 30 | 30.00% |
China | 6 | 6.00% |
France | 4 | 4.00% |
Ghana | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Daniel Vasella
- Personal Network